Sign in
Not yet recruitingPhase 1

Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B

Key facts

Who runs it
Xiamen Amoytop Biotech Co., Ltd.
Where
China3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 1
People taking part
60 people, planned
Starts
31 Dec 2026
Expected to end
Dec 2027
Type of study
Interventional, 4 groups
Treatments tested
  • ACT201 Injection
  • PegIFNα-2b Injection
  • Tenofovir Alafenamide Fumarate(TAF)
Record updated
18 November 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Voluntarily participate in this trial and sign the informed consent form
  • Aged 18 to 65 years (inclusive), male or female
  • Body mass index (BMI) between 18 and 32 kg/m² (inclusive)
  • HBsAg-positive or HBV DNA-positive for at least 6 months, or previous liver biopsy showing chronic HBV infection, or HBsAg-positive and anti-HBc IgM-negative at screening
  • No prior treatment with nucleos(t)ide analogues or interferons for chronic hepatitis B within 6 months before screening
  • HBsAg, HBeAg, HBV DNA and liver function indicators meet the protocol requirements
  • Willing to use effective contraception and have no plan for pregnancy, sperm donation or oocyte donation

Who cannot take part

  • Subjects with recent major trauma or major surgery, or those scheduled to undergo surgery
  • Prior solid organ or bone marrow transplantation
  • Prior or current use of prohibited medications
  • Concomitant hematological diseases
  • Participation in another clinical trial, or failure to complete the washout period specified in the protocol prior to this trial
  • Presence of clinically significant uncontrolled abnormalities or other severe diseases other than chronic HBV infection
  • History of other liver diseases
  • History of liver cirrhosis
  • Imaging suggestive of a suspected malignant hepatic lesion
  • History of extrahepatic diseases potentially associated with HBV immune status
  • Other diseases associated with vasculitis
  • Infections (other than HBV) requiring systemic antiviral or antibacterial therapy at screening
  • History of malignancy
  • Presence or history of severe psychiatric disorders
  • Severe retinopathy or other serious ophthalmic diseases
  • History of allergy
  • Any other condition that, in the opinion of the investigator, renders the subject unsuitable for participation in this trial
  • Abnormal laboratory findings
  • Lactating female subjects or those with a positive serum pregnancy test at screening
  • Past or current evidence of hepatic decompensation
  • Abnormal QTcF interval

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, randomized, open-label, parallel-controlled phase Ib clinical trial, which aims to evaluate the safety and preliminary efficacy of ACT201 injection combined with standard-of-care therapy (PegIFNα, NAs) in treatment-naive participants with chronic hepatitis B. A total of 60 treatment-naive participants with chronic hepatitis B are planned to be enrolled and randomized Treatment Group 1, Treatment Group 2, Treatment Group 3 or Treatment Group 4 for treatment.

The 4 groups in the trial

  • Group 1Treatment being tested

    Treatment: ACT201 Injection, PegIFNα-2b Injection, and Tenofovir Alafenamide Fumarate(TAF)

  • Group 2Treatment being tested

    Treatment: ACT201 Injection, PegIFNα-2b Injection, and Tenofovir Alafenamide Fumarate(TAF)

  • Group 3Treatment being tested

    Treatment: ACT201 Injection, PegIFNα-2b Injection, and Tenofovir Alafenamide Fumarate(TAF)

  • Group 4Treatment being tested

    Treatment: ACT201 Injection and Tenofovir Alafenamide Fumarate(TAF)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Open-Label Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B(CHB)
Criteria questions
Built from NCT07946757, who can take part
Record updated
18 November 2026